Drug Information

Drug General Information
Drug ID
D0A9OR
Former ID
DIB004604
Drug Name
SLV319
Indication Obesity [ICD9: 278; ICD10:E66] Discontinued in Phase 2 [547594]
Company
Solvay Pharmaceuticals
Target and Pathway
Target(s) Cannabinoid receptor 1 Target Info Antagonist [532030]
KEGG Pathway Rap1 signaling pathway
Neuroactive ligand-receptor interaction
Retrograde endocannabinoid signaling
PANTHER Pathway Endogenous cannabinoid signaling
Pathway Interaction Database N-cadherin signaling events
Reactome Class A/1 (Rhodopsin-like receptors)
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Small Ligand GPCRs
BDNF signaling pathway
GPCR ligand binding
GPCR downstream signaling
GPCRs, Other
References
Ref 547594Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017654)
Ref 532030JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.